U.K. House of Commons committee demands more clinical-trial transparency

09/18/2013 | PharmaTimes (U.K.)

A House of Commons Science and Technology Committee report says too many clinical trials remain unregistered and unpublished, and the lack of transparency undermines public trust, slows medical progress and potentially puts patients at risk. The committee does not advocate uncontrolled release of patient-level data, but does urge stronger government action to facilitate sharing of raw clinical-trial data.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ